Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Testolactone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 15/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Testolactone SCHEMBL2300061 | 0.94 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| Testolactone SCHEMBL4053 | 0.94 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| SCHEMBL8980363 | 0.79 | CYP19A1 (0.72) | CYP19A1LMNAMAPTCYP3A4 | |
| SCHEMBL23691780 | 0.78 | CYP19A1 (0.67) | CYP19A1LMNAMAPTCYP3A4 | |
| SCHEMBL8393653 | 0.76 | CYP19A1 (0.67) | CYP19A1LMNAMAPTCYP3A4 | |
| Androstenedone SCHEMBL14450072 | 0.75 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| Androstenedone SCHEMBL3758714 | 0.75 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| Androstenedone SCHEMBL1144460 | 0.75 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| Androstenedone SCHEMBL134061 | 0.75 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| Androstenedone SCHEMBL12430773 | 0.75 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | CYP19A1 3938/4885LMNA 415/4885MAPT 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.